cGMP

current Good Manufacturing Practice

The “c” is the most consequential letter in the acronym. It means the requirements are not frozen at the date they were written: manufacturers must use technologies and systems that are current, so a control that satisfied an inspector a decade ago may be inadequate today even though the regulation’s text has not changed. FDA has used this repeatedly — most visibly in data integrity, where expectations around audit trails and access control tightened sharply without any amendment to Part 211.

This is also why the US regulations are written broadly. 21 CFR 211 states requirements in general terms and leaves the detail to guidance, inspection practice, and industry standards, which can evolve without rulemaking. Arguing that a practice meets the literal text of the regulation is a weak position if the industry has plainly moved on; the standard is what is currently achievable and expected, not what was once accepted.

The practical implication is that compliance is a moving target requiring active surveillance. Sites need to track guidance, warning-letter themes, and updated standards, and periodically ask whether their controls are still current — not merely whether they are still as approved. Periodic review, gap assessment against new guidance, and remediation planning are how a system stays current rather than drifting into obsolescence.

• —“Current” means the expectation rises with technology and industry practice.
• —The regulation text can stay unchanged while the enforced standard moves — as it did for data integrity.
• —US regulations are written broadly so detail can evolve through guidance and inspection practice.
• —Meeting the literal text is a weak defence when industry practice has advanced.
• —Requires active surveillance of guidance, warning-letter themes, and updated standards.
• —Periodic review and gap assessment are how a quality system stays current.

21 CFR Parts 210 and 211 (current good manufacturing practice for finished pharmaceuticals); the FD&C Act §501(a)(2)(B), under which a drug not made in conformity with cGMP is deemed adulterated; interpreted through FDA guidance and inspection practice.